Jpmorgan Chase & CO Uni Qure N.V. Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Uni Qure N.V. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 969,504 shares of QURE stock, worth $4.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

969,504

Previous 749,354 29.38%

Holding current value

$4.34 Million

Previous $5.07 Million 0.63%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$4.82 - $6.93 $1.06 Million - $1.53 Million	220,150 Added 29.38%	969,504 $5.04 Million
Q4 2023 Feb 12, 2024	BUY	$5.63 - $8.27 $880,717 - $1.29 Million	156,433 Added 26.38%	749,354 $5.07 Million
Q3 2023 Nov 14, 2023	SELL	$6.71 - $11.83 $177,372 - $312,714	-26,434 Reduced 4.27%	592,921 $3.98 Million
Q2 2023 Aug 11, 2023	SELL	$11.12 - $22.2 $1.33 Million - $2.65 Million	-119,359 Reduced 16.16%	619,355 $7.1 Million
Q1 2023 May 11, 2023	BUY	$18.7 - $23.07 $1.26 Million - $1.56 Million	67,409 Added 10.04%	738,714 $14.9 Million

Q4 2022 Feb 13, 2023	SELL	$18.12 - $27.32 $1.12 Million - $1.7 Million	-62,055 Reduced 8.46%	671,305 $15.2 Million
Q3 2022 Nov 14, 2022	SELL	$16.98 - $25.54 $1.19 Million - $1.8 Million	-70,309 Reduced 8.75%	733,360 $13.8 Million
Q2 2022 Aug 11, 2022	SELL	$13.15 - $20.45 $1.07 Million - $1.66 Million	-81,151 Reduced 9.17%	803,669 $15 Million
Q1 2022 May 11, 2022	BUY	$14.54 - $21.5 $2.53 Million - $3.74 Million	174,069 Added 24.49%	884,820 $16 Million
Q4 2021 Feb 10, 2022	SELL	$20.24 - $36.01 $158,742 - $282,426	-7,843 Reduced 1.09%	710,751 $14.7 Million
Q3 2021 Nov 12, 2021	BUY	$26.01 - $38.22 $18.7 Million - $27.5 Million	718,594 New	718,594 $23 Million

Others Institutions Holding QURE

# of Institutions

148

Shares Held

34.1M

Call Options Held

1.07M

Put Options Held

603K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $209M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Uni Qure N.V. Transaction History